Skip to content
OpenCapital
Get started

Acrivon Therapeutics, Inc. ACRV Q3 2025 earnings

Reported November 13, 2025 · Before market open

EPS-$0.47Beat by $0.10
EPS estimate-$0.57

Next report

Aug 12, 2026 (In 2 weeks)
Revenue estimate$386.3K
EPS estimate-$0.49

Versus estimates

Diluted EPS

Q1 2026-$0.49In lineQ4 2025-$0.49In line
Q3 2025-$0.47Beat by $0.10
Q2 2025-$0.55Beat by $0.02Q1 2025-$0.51Beat by $0.06Q4 2024-$0.60Beat by $0.09

Ask the moment Acrivon Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Acrivon Therapeutics, Inc. report Q3 2025 earnings?
Acrivon Therapeutics, Inc. (ACRV) reported Q3 2025 earnings on November 13, 2025 before market open.
What were Acrivon Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Acrivon Therapeutics, Inc. reported eps of $-0.47 for Q3 2025.
Did Acrivon Therapeutics, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.57 by $0.10.
How did Acrivon Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 20.3% from $-0.59.
Where can I find Acrivon Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-280172) and the 10-Q periodic report (0001193125-25-280215) directly on SEC EDGAR. The filing index links above go to sec.gov.